Compare PSNYW & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSNYW | CERS |
|---|---|---|
| Founded | 2017 | 1991 |
| Country | Sweden | United States |
| Employees | 1686 | N/A |
| Industry | Auto Manufacturing | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.9M | 276.0M |
| IPO Year | N/A | 1996 |
| Metric | PSNYW | CERS |
|---|---|---|
| Price | $2.68 | $2.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.5K | ★ 2.4M |
| Earning Date | 03-06-2025 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,034,261,000.00 | $51,326,000.00 |
| Revenue This Year | N/A | $19.95 |
| Revenue Next Year | $79.49 | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $0.14 | $1.15 |
| 52 Week High | $7.50 | $3.15 |
| Indicator | PSNYW | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 48.93 |
| Support Level | $2.45 | $1.94 |
| Resistance Level | $3.50 | $2.68 |
| Average True Range (ATR) | 0.23 | 0.16 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 23.68 | 34.88 |
Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.